Viewing Study NCT05710367


Ignite Creation Date: 2025-12-25 @ 12:38 AM
Ignite Modification Date: 2025-12-27 @ 3:48 AM
Study NCT ID: NCT05710367
Status: UNKNOWN
Last Update Posted: 2023-02-02
First Post: 2023-01-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients
Sponsor: Albina Nowak, MD
Organization:

Study Overview

Official Title: Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients; A Prospective, Randomized, Double-Blind, Placebo- Controlled Study.
Status: UNKNOWN
Status Verified Date: 2023-01
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this clinical trial is to test dapagliflizone in Fabry patients. The main questions it aims to answer are:

* Has 10 mg/d of dapagliflozin a positive effect on kidney functions of Fabry patients.
* Has 10 mg/d of dapagliflozin a positive effect on heart functions in Fabry patients.

Participants will be asked to

* Sign an informed consent
* Give a blood and urine samples
* Be subjected to Echocardiography investigation
* Take 10 mg/day Dapagliflizone

Researchers will compare treatment to placebo groups to see if kidneys and heart functions will be improved in the treatment group better more than the placebo group.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: